SCHEMBL1461328

SCHEMBL1461328

N#Cc1ccc(OC2CCOCC2)nc1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TBK1 Q9UHD2 3/20 0.48
IKBKE Q14164 1/20 0.48
DPP4 P27487 2/20 0.45
DPP9 Q86TI2 2/20 0.45
DPP8 Q6V1X1 1/20 0.45
PDE10A Q9Y233 1/20 0.44
LRRK2 Q5S007 2/20 0.42
IP6K1 Q92551 1/20 0.40
AXL P30530 1/20 0.40
MERTK Q12866 1/20 0.40
PIK3R1 P27986 1/20 0.40
PIK3CA P42336 1/20 0.40
HSD11B1 P28845 2/20 0.39
ACACB O00763 1/20 0.39
DGAT1 O75907 1/20 0.39
PDE4B Q07343 1/20 0.38
PDE9A O76083 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29483220 1.00 TBK1 (0.48) TBK1IKBKEDPP4DPP9DPP8
SCHEMBL28698532 0.91 IKBKE (0.42) TBK1IKBKEDPP4DPP9DPP8
SCHEMBL25615427 0.89 DPP4 (0.52) DPP4DPP9DPP8IP6K1AXL
SCHEMBL30222295 0.89 DPP4 (0.52) DPP4DPP9DPP8IP6K1AXL
SCHEMBL2695269 0.86 DPP4 (0.53) DPP4DPP9DPP8IP6K1AXL
SCHEMBL2585221 0.84 DPP4 (0.52) DPP4DPP9DPP8IP6K1AXL
SCHEMBL941166 0.83 TDO2 (0.46) DPP4DPP9DPP8IP6K1AXL
Hydrochloric Acid SCHEMBL4714506 0.82 TDO2 (0.45) DPP4DPP9DPP8IP6K1AXL
SCHEMBL646276 0.82 DPP4 (0.47) DPP4DPP9DPP8IP6K1AXL
Hydrochloric Acid SCHEMBL2775641 0.82 TDO2 (0.45) DPP4DPP9DPP8IP6K1AXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240299559-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS AG (CH) 2024-09-12 US disclosed
CN-114181205-B Pyrazolopyridine compound or salt thereof, and preparation method and application thereof 励缔(杭州)医药科技有限公司 2024-06-11 CN disclosed
WO-2023069700-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS, INC. (US) 2023-04-27 WO disclosed
WO-2023069700-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS, INC. (US) 2023-04-27 WO disclosed
CN-114181205-A Pyrazolopyridine compound or salt thereof, and preparation method and application thereof 上海辉启生物医药科技有限公司 2022-03-15 CN disclosed
US-20120251551-A1 Substituted (Heteroarylmethyl)thiohydantoins BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-10-04 US disclosed
EP-2475653-A1 SUSTITUTED ( HETEROARYLMETHYL ) THIOHYDANTOINS AS ANTICANCER DRUGS Bayer Pharma Aktiengesellschaft (DE) 2012-07-18 EP disclosed
WO-2011029537-A1 SUSTITUTED ( HETEROARYLMETHYL ) THIOHYDANTOINS AS ANTICANCER DRUGS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-03-17 WO disclosed
WO-2009010784-A1 NEW COMPOUNDS 955 ASTRAZENECA AB (SE) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120251551-A1 Substituted (Heteroarylmethyl)thiohydantoins TPMT, BPHL, VHL TBK1 4700/4885IKBKE 1773/4885DPP4 1299/4885
US-20240299559-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF CDK2, SKP2, CDK1 TBK1 1689/4885IKBKE 355/4885DPP4 3596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.